Videos

Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.

An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.

Eric Nadler, MD, MPP, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial in extensive-stage small cell lung cancer.

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.

Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.

Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.

Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).

Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.

A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.

Andrew Zelenetz, MD, outlines the case of a 77-year-old man with chronic lymphocytic leukemia.

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

Gilles Salles, MD, the lymphoma service chief at Memorial Sloan Kettering Cancer Center discusses the safety profile of tafasitamab combined with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma, based on results of the L-MIND trial.

The progression of disease in MPNs and how genetic testing may inform therapy.

A discussion of the role of the JAK2 mutation and other factors in the development of MPNs.

Dr Verstovsek and Dr Kuykendall discuss the limitations of past treatments for MPNs.

Experts discuss the differences between essential thrombocythemia [ET], polycythemia vera [PV], and myelofibrosis [MF] and refinement of diagnosis.

Chevon Rariy, MD, discusses how the coronavirus disease 2019 pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.

Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.

Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.

Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.

David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.

Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.

An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.

Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.

Lara Traeger, PhD, discusses recommendations from the American Society of Clinical Oncology for coping with moral distress and burnout.